Alexandra Cantley
SelectiveNamed in filings at Polaris Partners
- Board seats filed
- 8
all filings on record
Named in filings at Polaris Partners
all filings on record
last 24 months
from a verified or cited source
| Cirrus Therapeutics | Biotech & pharma | August 2025 | None on file |
| TRex Holdings | Biotech & pharma | November 2024 | SV Life Sciences, Virtuoso-mccarran |
| Crossbow Therapeutics | Biotech & pharma | March 2023 | MPM BioVentures |
| BeMe Health | Digital health | November 2022 | Flare Capital |
| Auron Therapeutics | Biotech & pharma | July 2022 | None on file |
| EpiBiologics | Biotech & pharma | March 2022 | None on file |
| Podimetrics | Digital health | December 2021 | None on file |
| Glympse Bio | Biotech & pharma | July 2018 | Aspect Ventures, CRV, Kendall Capital Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Alexandra Cantley on the board, based on 8 filed seats with a verified or cited source.